Skip to main content
Intended for US healthcare providers only.

IMPORTANT INFORMATION

TRUSELTIQ® (INFIGRATINIB) CAPSULES
NOTICE OF PERMANENT DISCONTINUATION OF DISTRIBUTION

October 2022

Dear Healthcare Provider:

The purpose of this letter is to inform you that Helsinn Therapeutics (U.S.), Inc. will discontinue distribution of TRUSELTIQ® (infigratinib) capsules in the first quarter of 2023 and is now ending all promotional and educational activities.

Importantly, this discontinuation is not for safety or efficacy reasons, but is based on difficulties in recruiting and enrolling study subjects for the required confirmatory clinical trial.

We strongly recommend that, effective immediately, you not start any new patients on TRUSELTIQ®. If you have patients who are currently taking TRUSELTIQ® and you want to keep them on treatment, we anticipate supplies of the product will be available until March 31, 2023. We expect that you will determine the best treatment plan for patients currently taking TRUSELTIQ® based on your independent medical judgement.

If you have any questions about this discontinuation or about TRUSELTIQ®, please contact the Helsinn Medical Information Department at 1-855-541-3495.

Please share this important information with the other relevant healthcare providers in your practice, including physicians, pharmacists, and other staff.